FDA 483 - Tianjin Tianyao Pharmaceuticals Co., Ltd. - May 24, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Tianjin Tianyao Pharmaceuticals Co., Ltd, an API manufacturer in Tianjin, China, revealed significant deficiencies in laboratory controls and equipment maintenance. Observations included inadequate investigation of system suitability deviations, presence of particles in manufacturing equipment, and insufficient analytical procedures for starting materials and method validation for forced degradation studies. These issues suggest a lack of robust quality control and manufacturing oversight.
ID · 1b7f892f-d219-4074-913a-f0dcc7b09074